PRESENCE OF THE TUMOR-ASSOCIATED ANTIGENS CA-50 AND CA-19-9 IN ENDOMETRIAL CANCER

被引：0
|
作者：
GOHRING, UJ
WEBER, F
SCHARL, A
BOLTE, A
机构：
[1] Universitäts-Frauenklinik Köln, Köln, D-50937
来源：
ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 1993年 / 254卷 / 1-4期
关键词：
D O I：
10.1007/BF02266273
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
[No abstract available]
引用
收藏
页码：993 / 995
页数：3
相关论文
共 50 条
  • [31] STRUCTURAL STUDIES ON ONCOFETAL CARBOHYDRATE ANTIGENS (CA-19-9, CA-50, AND CA-125) CARRIED BY O-LINKED SIALYLOLIGOSACCHARIDES ON HUMAN AMNIOTIC MUCINS
    HANISCH, FG
    UHLENBRUCK, G
    PETERKATALINIC, J
    EGGE, H
    CARBOHYDRATE RESEARCH, 1988, 178 : 29 - 47
  • [32] COMPARISON OF A NEW TUMOR-MARKER CA-242 WITH CA-19-9, CA-50 AND CARCINOEMBRYONIC ANTIGEN (CEA) IN DIGESTIVE-TRACT DISEASES
    KUUSELA, P
    HAGLUND, C
    ROBERTS, PJ
    BRITISH JOURNAL OF CANCER, 1991, 63 (04) : 636 - 640
  • [33] THE PLACE OF TUMOR-ASSOCIATED ANTIGEN CA-19-9 IN THE DIFFERENTIAL-DIAGNOSIS OF PANCREATIC DISEASE
    HEPTNER, G
    DOMSCHKE, S
    SCHNEIDER, MU
    DOMSCHKE, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (16) : 624 - 628
  • [34] COMPARISON OF PORTAL AND PERIPHERAL-BLOOD LEVELS OF CARCINOEMBRYONIC ANTIGEN, CA-19-9, AND CA-125 TUMOR-ASSOCIATED ANTIGENS IN PATIENTS WITH COLORECTAL AND PANCREATIC-CANCER
    TALBOT, RW
    NAGORNEY, DM
    PEMBERTON, JH
    WIEAND, HS
    RITTS, RE
    CANCER RESEARCH, 1989, 49 (03) : 542 - 543
  • [35] THE PATTERNS OF COEXPRESSION OF TUMOR-ASSOCIATED ANTIGENS CA-19-9, TAG-72, AND DU-PAN-2 IN HUMAN PANCREATIC-CANCER
    TOSHKOV, I
    MOGAKI, M
    KAZAKOFF, K
    POUR, PM
    INTERNATIONAL JOURNAL OF PANCREATOLOGY, 1994, 15 (02) : 97 - 103
  • [36] THE TUMOR-ASSOCIATED ANTIGEN CA-50 IN THE DIFFERENTIAL-DIAGNOSIS OF CHRONIC-PANCREATITIS (CHP) AND PANCREATIC-CANCER (PC) - COMPARISON WITH CA 19-9 AND CA 12-5
    PASQUALI, C
    SPERTI, C
    DANDREA, AA
    CATALINI, S
    DELUCA, A
    BONADIMANI, B
    CAPPELLAZZO, F
    PEDRAZZOLI, S
    DIGESTION, 1986, 35 (01) : 45 - 46
  • [37] THE CLINICAL VALIDITY OF CIRCULATING TUMOR-ASSOCIATED ANTIGENS CEA AND CA-19-9 IN PRIMARY DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH GASTROINTESTINAL MALIGNANCIES
    STAAB, HJ
    BRUMMENDORF, T
    HORNUNG, A
    ANDERER, FA
    KIENINGER, G
    KLINISCHE WOCHENSCHRIFT, 1985, 63 (03): : 106 - 115
  • [38] CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma
    Pectasides, D
    Mylonakis, A
    Kostopoulou, M
    Papadopoulou, M
    Triantafillis, D
    Varthalitis, J
    Dimitriades, M
    Athanassiou, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 348 - 353
  • [39] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) IN PATIENTS WITH COLORECTAL-CANCER - A COMPARISON WITH CEA, CA-50 AND CA-242
    PASANEN, P
    ESKELINEN, M
    KULJU, A
    PENTTILLA, I
    JANATUINEN, E
    ALHAVA, E
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 (02): : 119 - 124
  • [40] CLINICAL-EXPERIENCE WITH THE NEW TUMOR-ASSOCIATED ANTIGEN CA-19-9 COMPARED WITH CEA IN DIFFERENT NEOPLASMS
    PFEIFFER, R
    DIMITRIADIS, K
    BALZER, K
    GIESCHE, U
    AULBERT, E
    HOFFMANN, B
    SCHMIDT, CG
    TUMORDIAGNOSTIK & THERAPIE, 1984, 5 (05) : 196 - 200
12345